Antiviral drug

AIM ImmunoTech Announces Phase 2a Human Challenge Trial to Test its Drug Ampligen as an Intranasal Antiviral Prophylactic Therapy

Retrieved on: 
Friday, July 9, 2021
Health sciences, Health, Medicine, Drug discovery, Rintatolimod, AIM ImmunoTech, Common cold, Rhinovirus, Antiviral drug, Therapy, Live attenuated influenza vaccine, Nasal administration

OCALA, Fla., July 09, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test the companys drug Ampligen as a potential intranasal antiviral therapy using a human Rhinovirus hRV (common cold virus) and Influenza.

Key Points: 
  • OCALA, Fla., July 09, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test the companys drug Ampligen as a potential intranasal antiviral therapy using a human Rhinovirus hRV (common cold virus) and Influenza.
  • In an HCT, subjects are intentionally exposed to particular diseases to test how the diseases will respond to potential therapeutics.
  • This Phase 2a study will come in the wake of AIMs recent announcement that all subjects have completed treatment in the companys Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as a potential intranasal therapy.
  • Open Orphan has a leading portfolio of eight human challenge study models for conditions such as RSV, flu, asthma and COPD.

COVID-19 Treatment Clinical Landscape Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 9, 2021
Health, Pharmaceutical, Medicine, Clinical medicine, Medical specialties, Antiviral drug, Biocides, Hyperimmune, Immunology, Immunotherapy, COVID-19, Monoclonal antibody

The "Disease Analysis: COVID-19 Treatment" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disease Analysis: COVID-19 Treatment" report has been added to ResearchAndMarkets.com's offering.
  • The commercial outlook for COVID-19 therapeutics is expected to decline progressively throughout 2021 due to the phased implementation of global vaccination programs, which should substantially reduce both outpatient and hospital COVID-19 cases.
  • Veklury faces myriad threats from pipeline candidates, including antivirals, immunomodulatory agents, monoclonal antibodies, and hyperimmune globulin therapies.
  • The overall likelihood of approval of a Phase I antiviral asset is 12.9%, and the average probability a drug advances from Phase III is 68.5%.

Verge Genomics Presents Preclinical Data Supporting Broad-Spectrum Potential of Its Novel, Oral Antiviral at the 31st European Congress of Clinical Microbiology & Infectious Diseases

Retrieved on: 
Wednesday, July 7, 2021
Health, Infectious diseases, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Coronaviridae, Sarbecovirus, Antiviral drug, Severe acute respiratory syndrome, COVID-19 drug repurposing research, GC376, the Preclinical Study, PIKfyve, Verge Genomics, THE PRECLINICAL STUDY, PIKFYVE, VERGE GENOMICS

The results will be presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) online meeting being held July 9-12, 2021.

Key Points: 
  • The results will be presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) online meeting being held July 9-12, 2021.
  • There remains an urgent need for oral antiviral treatments for SARS-CoV-2 and its variants, said Alice Zhang, CEO and Co-Founder of Verge Genomics.
  • Verge has demonstrated potent antiviral activity in vitro and improvement of SARS-CoV-2-induced pathology in vivo by the PIKfyve inhibitor, VRG101.
  • Verge is focused on developing therapeutics for serious genetic diseases using human genomics and machine learning.

Swedish Company Announces New Product VirusShield, A Self-Adhesive Antimicrobial Protection Film That Kills Germs

Retrieved on: 
Monday, July 5, 2021
Biocides, Chemistry, Physical sciences, Natural sciences, Antimicrobial, Copper, Antiviral drug

VirusShield is a self-adhesive antiviral and antimicrobial film that can be placed on surfaces like doorknobs, handles, etc.

Key Points: 
  • VirusShield is a self-adhesive antiviral and antimicrobial film that can be placed on surfaces like doorknobs, handles, etc.
  • The product uses an advanced but simple technique of copper formulation that prevents the growth of microbes on surfaces and prevents the spread of Covid-19 and other germs.
  • Most methods of getting rid of germs are either not sustainable, less effective, or involve chemicals, whichdo more harm than good.
  • The copper film works on a scientific principle of copper ions, making it impossible for microbes to thrive on it.

Atea’s AT-527, an Oral Antiviral Drug Candidate, Reduces Viral Replication in Hospitalized Patients with COVID-19 in Phase 2 Interim Analysis

Retrieved on: 
Wednesday, June 30, 2021
Coronaviridae, Sarbecovirus, Severe acute respiratory syndrome coronavirus, Antiviral drug, Severe acute respiratory syndrome

Roche and Atea are jointly developing AT-527, an oral direct-acting antiviral (DAA) agent derived from Ateas purine nucleotide prodrug platform.

Key Points: 
  • Roche and Atea are jointly developing AT-527, an oral direct-acting antiviral (DAA) agent derived from Ateas purine nucleotide prodrug platform.
  • The interim analysis of the Phase 2 study included data from 70 hospitalized, high-risk patients with COVID-19 of which data from 62 patients were evaluable for virology analysis.
  • AT-527s SARS-CoV-2 potent antiviral activity was also observed in patients with higher baseline viral loads above the median of 5.26 log10 as compared to placebo.
  • We are very pleased with the potent antiviral activity of AT-527 demonstrated by the rapid inhibition of SARS-CoV-2 replication.

Venatorx Pharmaceuticals Names Mary Beth Dorr, Ph.D. Vice President, Clinical Science

Retrieved on: 
Tuesday, June 29, 2021
Research, Human resources, Infectious diseases, Clinical trials, Professional services, Biotechnology, Health, Pharmaceutical, Science, Articles, Life sciences, Health sciences, Antiviral drug, Biocides, Antimicrobial resistance, Infection, ViroPharma, Rudi Pauwels

Venatorx Pharmaceuticals today announced that Mary Beth Dorr, Ph.D. has joined the Company as Vice President, Clinical Science.

Key Points: 
  • Venatorx Pharmaceuticals today announced that Mary Beth Dorr, Ph.D. has joined the Company as Vice President, Clinical Science.
  • Founded in 2010, Venatorx Pharmaceuticals is a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with multi-drug-resistant bacterial infections and hard-to-treat viral infections.
  • In addition, Venatorx is in Phase 1 with its first antiviral compound (VNRX-9945), a Hepatitis B virus inhibitor.
  • For more information about Venatorx, its partners, investors and pipeline development, please visit www.venatorx.com .

Venatorx Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of VNRX-9945 for the Treatment of Chronic Hepatitis B Virus Infection

Retrieved on: 
Monday, June 28, 2021
Women, Other Science, FDA, Research, General Health, MEN, Family, Public policy, Government, Consumer, Pharmaceutical, Oncology, Healthcare reform, Children, Infectious diseases, Baby, Maternity, LGBTQ+, Clinical trials, Biotechnology, Health, Science, Medical specialties, Clinical medicine, Medicine, Hepadnaviridae, Infectious causes of cancer, Hepatitis B, Hepatitis, Antiviral drug, Transmission of hepadnaviruses, Viral hepatitis

Venatorx Pharmaceuticals today announced that the first patient was dosed in a Phase 1 clinical trial evaluating VNRX-9945, a highly potent, broadly active viral replication inhibitor for the treatment of chronic hepatitis B virus (HBV) infection.

Key Points: 
  • Venatorx Pharmaceuticals today announced that the first patient was dosed in a Phase 1 clinical trial evaluating VNRX-9945, a highly potent, broadly active viral replication inhibitor for the treatment of chronic hepatitis B virus (HBV) infection.
  • We believe combination regimens that include VNRX-9945 have the potential to lead to said functional cure in chronic HBV patients.
  • In addition, Venatorx is in Phase 1 with its first antiviral compound (VNRX-9945), a Hepatitis B virus inhibitor.
  • Capsid assembly modulators have a dual mechanism of action in primary human hepatocytes infected with hepatitis B virus.

Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter

Retrieved on: 
Wednesday, June 23, 2021
Antiviral drug, Biocides, Orthomyxoviridae, Biology

We recently completed a 14-day GLP toxicology study, which was the final pre-IND enabling step prior to advancing this potent inhibitor into a first-in-human study.

Key Points: 
  • We recently completed a 14-day GLP toxicology study, which was the final pre-IND enabling step prior to advancing this potent inhibitor into a first-in-human study.
  • There is a pressing need for new antivirals to treat influenza, as currently approved antiviral therapeutics are prone to viral resistance, added Dr. Lee.
  • CC-42344 stops the first step of viral replication by binding to a highly conserved PB2 site of the influenza polymerase complex that is essential to replication.
  • In preparing to initiate this study, we have already established a subsidiary in Australia and have selected a contract research organization.

Significant Discovery Reveals New Antiviral Properties of Tetra Bio-Pharma's Innovative Drug ARDS-003

Retrieved on: 
Monday, June 21, 2021
Medical specialties, Health, Medicine, Antiviral drug, Biocides, Acute respiratory distress syndrome, Virus

On March 26, 2021, Tetra announced it had entered into an agreement with Targeted Pharmaceuticals to initiate additional studies on its leading drug candidate ARDS-003.

Key Points: 
  • On March 26, 2021, Tetra announced it had entered into an agreement with Targeted Pharmaceuticals to initiate additional studies on its leading drug candidate ARDS-003.
  • In other words, it clears the virus significantly better than the standard antiviral drug alone.
  • These results suggest that in addition to immunomodulator properties, ARDS-003 demonstrates strong antiviral effects in humans.
  • The College of Science at Mason is a leader in scientific discovery creating innovative solutions for the rapidly changing needs of today's world.

Appili Therapeutics Inc. Expands PRESECO Clinical Trial of Avigan®/Reeqonus™ for Mild-to-Moderate COVID-19 Patients into Mexico and Brazil

Retrieved on: 
Thursday, June 17, 2021
General Health, Infectious diseases, Health, Pharmaceutical, Clinical trials, Pharmaceutical industry, Health sciences, Antiviral drug, Biocides, Life sciences, Medication, Natural sciences, the PRESECO Clinical Trial, Avigan/Reeqonus, Appili Therapeutics, THE PRESECO CLINICAL TRIAL, AVIGAN/REEQONUS, APPILI THERAPEUTICS

With the addition of the new sites, Appili expects to complete enrollment and report top-line results by the end of September.

Key Points: 
  • With the addition of the new sites, Appili expects to complete enrollment and report top-line results by the end of September.
  • Here and abroad, physicians and government leaders have been calling for effective oral antiviral medicines to treat these patients.
  • With cases decreasing in the U.S. our clinical expansion into Brazil and Mexico will help us meet our enrollment goal.
  • As part of the expansion and prioritization of the PRESECO treatment study, Appili has ended its CONTROL trial.